Search
Eculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria … Eculizumab is a monoclonal antibody that targets complement protein C5.
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigationalPolatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalImatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. … Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".
Tolcapone
go.drugbank.com/drugs/DB00323ApprovedInvestigationalWithdrawnTolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. … It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Hydrocodone
go.drugbank.com/drugs/DB00956ApprovedIllicitInvestigationalHydrocodone is a synthetic opioid derivative of codeine.[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. … Hydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain.
Saprisartan
go.drugbank.com/drugs/DB01347ExperimentalSaprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. … It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [A14009].
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor BlockersEnoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnIt is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries. … Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.
Categories: Compounds used in a research, industrial, or household settingOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Cladribine
go.drugbank.com/drugs/DB00242ApprovedInvestigational[A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718] … [A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell
Secnidazole
go.drugbank.com/drugs/DB12834ApprovedInvestigational[A245503] Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. … It is structurally related to other 5-nitroimidazoles, including [DB00916] and [DB00911], but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class